Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
Malariavaccin PfSPZ-GA1 veroorzaakt in eerste trial geen bijwerkingen
dec 2017 | Parasitaire infecties